Table 1.
Baseline demographic and clinical characteristics of the 149 study participants with adequate biopsy data.
| Statistic | |
|---|---|
| Gender (% Male) | 89 (60%) |
| Age (years) | 50 (±13) |
| Liver transplant | 34 (23%) |
| Anthropometric data | |
| Weight (kg) | 85 (±19) |
| BMI (kg/m2) | 29·7 (±6·7) |
| Waist:Hip Ratio | |
| Male | 0·95 (±0·08) |
| Female | 0·86 (±0·09) |
| Liver Enzymes | |
| Bilirubin (IU/L) | 13 (8–18) |
| Alanine aminotransferase (IU/L) | 58 (34–110) |
| Aspartate aminotransferase (IU/L) | 47 (30–80) |
| Gamma-glutamyl transpeptidase (IU/L) | 103 (52–244) |
| Alkaline phosphatase (IU/L) | 103 (78–165) |
| Fibrosis stage (modified Ishak score) | |
| 0 | 30 (20%) |
| 1 | 27 (18%) |
| 2 | 24 (16%) |
| 3 | 33 (22%) |
| 4 | 9 (6%) |
| 5 | 7 (5%) |
| 6 | 18 (12%) |
| Final diagnosis post biopsy | |
| NAFLD | 53 (36%) |
| Autoimmune liver disease | 25 (17%)* |
| Viral hepatitis | 20 (13%)** |
| Normal | 12 (8%) |
| Other | 39 (26%) |
Data reported as mean (±SD), median (IQR), or n (%), as applicable. *13 AIH, 3 PBC, 3 PSC, 6 overlap syndromes and autoimmune cholangiopathies. **13 patients post-transplant.